ClinicalTrials.gg
RecruitingNCT04895709Updated Aug 17, 2026

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of BMS-986340 and BMS-936558-01 in Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma and Microsatellite Stable Colorectal Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 47 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
38th of 678
1,109 · median 71
Started
2021
with 46 others
Phase 1/2
74 of 834
23 open now
Primary completion
2031-08
later than 209 of 218 live
Registered
615th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 38th largest by planned enrollment of the 678 interventional ones that give a count, is one of 47 that started in 2021, is one of 74 in phase 1/2, reaches primary completion later than 209 of the 218 other live ones, and was the 615th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

140 more — sign in →

All 145 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

03

Conditions studied

  • Cervical Cancer
  • Gastric/Gastroesophageal Junction Adenocarcinoma
  • Microsatellite Stable Colorectal Cancer
  • Non-Small-Cell Lung Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Renal Cell
  • Urothelial Carcinoma
  • Pancreatic Adenocarcinoma
  • Melanoma
  • Ovarian Neoplasms
  • Triple Negative Breast Neoplasms

Keywords

  • BMS-986340
  • Cervical Cancer
  • CRC
  • First-in-human
  • GEJ
  • Gastric/Gastroesophageal Junction Adenocarcinoma
  • HNSCC
  • Microsatellite Stable Colorectal Cancer
  • MSS CRC
  • Nivolumab
  • Non-Small-Cell Lung Cancer
  • NSCLC
  • SCCHN
  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Renal Cell
  • Urothelial Carcinoma
  • Pancreatic Adenocarcinoma
  • Melanoma
  • Ovarian Neoplasms
  • Triple Negative Breast Neoplasms
  • Docetaxel
  • Pumitamig
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fresh pre-treatment and on-treatment tumor must be provided for biomarker analysis.
  • per (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
  • Performance Status of 0 or 1.
  • Radiographically documented progressive disease on or after the most recent therapy.
  • Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/ setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
  • Advanced or metastatic disease and have received, be to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.

Exclusion criteria

Exclusion Criteria

  • Women who are pregnant or breastfeeding.
  • Primary central nervous system (CNS) .
  • Untreated .
  • .
  • Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.
  • Active, known, or suspected disease.
  • Condition requiring systemic treatment with either within 14 days or other medications within 30 days of the first dose of study treatment.
  • Prior organ or tissue allograft.
  • Uncontrolled or significant cardiovascular disease.
  • Major surgery within 4 weeks of study drug administration.
  • History of or with active interstitial lung disease or pulmonary fibrosis.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,109 participants (estimated)

Study arms

  • Experimental
    Part 1A: BMS-986340 Dose Escalation

    Drug: BMS-986340

  • Experimental
    Part 2A: BMS-986340 Dose Expansion

    Drug: BMS-986340

  • Experimental
    Part 1B: BMS-986340 + Nivolumab Dose Escalation

    Drug: BMS-986340 · Drug: BMS-936558-01

  • Experimental
    Part 2B: BMS-986340 + Nivolumab Dose Expansion

    Drug: BMS-986340 · Drug: BMS-936558-01

  • Experimental
    Part 1C: BMS-986340 + Docetaxel Dose Escalation

    Drug: BMS-986340 · Drug: Docetaxel

  • Experimental
    Part 1A-J: BMS-986340 Dose Escalation

    Drug: BMS-986340

  • Experimental
    Part 1B-J: BMS-986340 + Nivolumab Dose Escalation

    Drug: BMS-986340 · Drug: BMS-936558-01

  • Experimental
    Part 2C: BMS-986340 + Docetaxel Dose Expansion

    Drug: BMS-986340 · Drug: Docetaxel

  • Experimental
    Part 2D: BMS-986340 + Pumitamig Dose Expansion

    Drug: BMS-986340 · Drug: Pumitamig

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Nivolumab

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: BMS-986545, BNT327

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 120 weeks

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to 120 weeks

  3. Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria

    Time frame: Up to either 21 or 28 days

  4. Incidence of AEs leading to discontinuation

    Time frame: Up to 120 weeks

  5. Number of deaths

    Time frame: Up to 120 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) parameters of BMS-986340 administered as monotherapy: Maximum concentration (Cmax)

    Time frame: Up to 120 weeks

  2. PK parameters of BMS-986340 administered as monotherapy: Time to maximum concentration (Tmax)

    Time frame: Up to 120 weeks

  3. PK parameters of BMS-986340 administered as monotherapy: Area under the concentration-time curve 1 dosing interval (AUC (TAU))

    Time frame: Up to 120 weeks

  4. PK parameters of BMS-986340 administered as monotherapy: Observed concentration at the end of the dosing interval (Ctau)

    Time frame: Up to 120 weeks

  5. PK parameters of BMS-986340 administered in combination with nivolumab: Maximum concentration (Cmax)

    Time frame: Up to 120 weeks

  6. PK parameters of BMS-986340 administered in combination with docetaxel: Cmax

    Time frame: Up to 120 weeks

  7. PK parameters of BMS-986340 administered in combination with nivolumab: Time to maximum concentration (Tmax)

    Time frame: Up to 120 weeks

  8. PK parameters of BMS-986340 administered in combination with docetaxel: Tmax

    Time frame: Up to 120 weeks

  9. PK parameters of BMS-986340 administered in combination with nivolumab: Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to 120 weeks

  10. PK parameters of BMS-986340 administered in combination with docetaxel: AUC(TAU)

    Time frame: Up to 120 weeks

  11. PK parameters of BMS-986340 administered in combination with nivolumab: Observed concentration at the end of the dosing interval (Ctau)

    Time frame: Up to 120 weeks

  12. PK parameters of BMS-986340 administered in combination with docetaxel: Ctau

    Time frame: Up to 120 weeks

  13. PK parameters of BMS-986340 administered in combination with pumitamig: Cmax

    Time frame: Up to 120 weeks

  14. PK parameters of BMS-986340 administered in combination with pumitamig: Tmax

    Time frame: Up to 120 weeks

  15. PK parameters of BMS-986340 administered in combination with pumitamig: AUC(TAU)

    Time frame: Up to 120 weeks

  16. PK parameters of BMS-986340 administered in combination with pumitamig: Ctau

    Time frame: Up to 120 weeks

  17. Incidence of anti-drug antibodies to BMS- 986340 when administered as monotherapy

    Time frame: Up to 120 weeks

  18. Incidence of anti-drug antibodies to BMS- 986340 when administered in combination with nivolumab

    Time frame: Up to 120 weeks

  19. Incidence of anti-drug antibodies to BMS- 986340 when administered in combination with docetaxel

    Time frame: Up to 120 weeks

  20. Incidence of anti-drug antibodies to BMS-986340 when administered in combination with pumitamig

    Time frame: Up to 120 weeks

  21. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator

    Time frame: At 6 months, 12 months

  22. Disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator

    Time frame: At 6 months, 12 months

  23. Duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator

    Time frame: At 6 months, 12 months

  24. Progression-free survival rate (PFSR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator

    Time frame: At 6 months, 12 months

07

Study locations

39 of 47 sites recruiting
  • Community Cancer Institute
    Clovis, California 93611, United States
    Recruiting
    • Uzair Chaudhary, Site 0032 · Contact559-387-1600
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Anthony El-Khoueiry, Site 0041 · Contact323-865-3967
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
    • Carlos Becerra, Site 0050 · Contact949-764-8222
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Douglas Laux, Site 0062 · Contact319-356-1032
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Martin Gutierrez, Site 0007 · Contact551-996-5863
  • Local Institution - 0006
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0002
    New York, New York 10065, United States
    Completed

    Not enrolling at this site — choose another above.

  • Providence Cancer Center Oncology and Hematology Care- Eastside
    Portland, Oregon 97213, United States
    Recruiting
    • Rom Leidner, Site 0001 · Contact503-215-5696
  • Local Institution - 0063
    Nashville, Tennessee 37204, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Jordan Berlin, Site 0052 · Contact615-936-1796
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Maen Abdelrahim, Site 0061 · Contact346-241-5495
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
    Recruiting
    • Adnan Nagrial, Site 0057 · Contact+61 02 86705071
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
    Recruiting
    • Abhijit Pal, Site 0058 · Contact61287389744
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
    Recruiting
    • Aaron Hansen, Site 0054 · Contact61731765564
  • Cabrini Hospital - Malvern
    Malvern, Victoria 3144, Australia
    Recruiting
    • Shehara Mendis, Site 0053 · Contact(03)95083434
  • St Vincent's Hospital
    Melbourne, Victoria 3065, Australia
    Recruiting
    • Melissa Moore, Site 0055 · Contact61392313155
  • One Clinical Research
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Muhammad Khattak, Site 0056 · Contact+61 08 6279 9466
  • Cross Cancer Institute
    Edmonton, Alberta T6X 1E8, Canada
    Recruiting
    • Quincy Chu, Site 0027 · Contact7804328248
  • Local Institution - 0030
    Vancouver, British Columbia V5Z 4E6, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Hamilton Health Sciences-Juravinski Cancer Centre
    Hamilton, Ontario L8V5C2, Canada
    Recruiting
    • Sebastien Hotte, Site 0029 · Contact905-387-9495
  • Local Institution - 0009
    Toronto, Ontario M5G 2M9, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Centre Hospitalier de luniversite de Montreal
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
    • Rahima Jamal, Site 0015 · Contact51489080008444
  • Local Institution - 0016
    Ottawa, K1H 8L6, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 0044
    Ulm, Baden-Wurttemberg 89081, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit
    Dresden, 01307, Germany
    Recruiting
    • Martin Wermke, Site 0010 · Contact+493514587566
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
    Recruiting
    • Stefan Kasper-Virchow, Site 0018 · Contact00492017233449
  • Universitatsklinikum Frankfurt
    Frankfurt, 60590, Germany
    Recruiting
    • Martin Sebastian, Site 0020 · Contact+496963016217
  • Universitaetsklinikum Wuerzburg
    Würzburg, 97078, Germany
    Recruiting
    • Cyrus Sayehli, Site 0019 · Contact4993120140964
  • Rabin Medical Center
    Petah Tikva, Central District 4941492, Israel
    Recruiting
    • Salomon Stemmer, Site 0036 · Contact97239378076
  • Local Institution - 0035
    Ramat Gan, Central District 5265601, Israel
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sheba Medical Center
    Ramat Gan, Central District 5265601, Israel
    Recruiting
    • Tamar Beller, Site 0038 · Contact97235302542
  • Rambam Health Care Campus
    Haifa, Northern District 3109601, Israel
    Recruiting
    • Talia Shentzer Kutiel, Site 0039 · Contact97247776700
  • Sourasky Medical Center
    Tel Aviv, Tell Abīb 6423906, Israel
    Recruiting
    • Ravit Geva, Site 0037 · Contact97236973082
  • Humanitas
    Rozzano, Milano 20089, Italy
    Recruiting
    • Matteo Simonelli, Site 0023 · Contact+390282244559
  • Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
    Candiolo, Torino 10060, Italy
    Recruiting
    • Vanesa Gregorc, Site 0033 · Contact390119933250
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1
    Milan, 20133, Italy
    Recruiting
    • Filippo De Braud, Site 0024 · Contact390223903066
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    Naples, 80131, Italy
    Recruiting
    • Paolo Ascierto, Site 0034 · Contact390815903431
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
    Recruiting
    • Gennaro Daniele, Site 0040 · Contact+390630153446
  • ospedale le scotte-U.O.C. Immunoterapia Oncologica
    Siena, 53100, Italy
    Recruiting
    • Michele Maio, Site 0025 · Contact390577586335
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Yasutoshi Kuboki, Site 0064 · Contact81471331111
  • Hospital Universitario Virgen de la Victoria
    Málaga, Andalusia 29010, Spain
    Recruiting
    • Javier Garcia Corbacho, Site 0048 · Contact951032250
  • Institut Catalan d Oncologia (ICO) - Badalona
    Badalona, Barcelona [Barcelona] 08916, Spain
    Recruiting
    • Cinta Hierro Carbo, Site 0014 · Contact34934978925
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Elena Garralda Cabanas, Site 0049 · Contact349327460004910
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
    Recruiting
    • Luis Paz-Ares Rodriguez, Site 0047 · Contact0034913908922
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD
    Madrid, 28040, Spain
    Recruiting
    • Victor Moreno Garcia, Site 0013 · Contact915504800ext2805
  • Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid-CIOCC
    Madrid, 28050, Spain
    Recruiting
    • Emiliano Calvo, Site 0011 · Contact+34934894304
  • Clinica Universidad de Navarra-oNCOLOGY
    Pamplona, 31008, Spain
    Recruiting
    • Ignacio Melero Bermejo, Site 0012 · Contact34948255400
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Aug 2031, 123 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's planned 123 months is above that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 20, 2021
StartActual
May 27, 2021
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04895709
Responsible party
Sponsor
First posted
May 20, 2021
Start date
May 27, 2021
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Aug 17, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imzokitug

Start the discussion